Asset Details
Do you wish to reserve the book?
Disease‐Associated Risk Variants and Expression Levels of the lncRNA, CDKN2B‐AS1, Are Associated With the Progression of HCC
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Disease‐Associated Risk Variants and Expression Levels of the lncRNA, CDKN2B‐AS1, Are Associated With the Progression of HCC
Do you wish to request the book?
Disease‐Associated Risk Variants and Expression Levels of the lncRNA, CDKN2B‐AS1, Are Associated With the Progression of HCC
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Disease‐Associated Risk Variants and Expression Levels of the lncRNA, CDKN2B‐AS1, Are Associated With the Progression of HCC
2025
Overview
The most susceptible loci of hepatocellular carcinoma (HCC) identified by genome‐wide association studies are located in non‐coding regions. The antisense non‐coding RNA at the INK4 locus (ANRIL), also known as cyclin‐dependent kinase inhibitor 2B antisense RNA 1 (CDKN2B‐AS1), is a long non‐coding (lnc)RNA situated within and antisense to genes encoding CDKN2A/B on chromosome 9p21.3. Single‐nucleotide polymorphisms (SNPs) within CDKN2B‐AS1 are associated with several cancer types, but their impacts on HCC remain unclear. In this study, we investigated the effects of CDKN2B‐AS1 SNPs on both the susceptibility to HCC and its clinicopathological development. Five CDKN2B‐AS1 SNP loci—rs564398 (T/C), rs1333048 (A/C), rs1537373 (G/T), rs2151280 (A/G) and rs8181047 (G/A)—were analysed using a TaqMan allelic discrimination assay for genotyping in a cohort of 810 HCC patients and 1190 healthy controls. Under the dominant model, HCC patients with at least one minor C‐allele of rs564398 showed a lower risk of liver cirrhosis (odds ratio (OR) = 0.677). Additionally, HCC patients with the GT + TT genotype of rs1537373 had a reduced risk of developing large tumours (T3 + T4) and advanced clinical stages (III/IV), particularly in the male population (OR = 0.644 and 0.679). Furthermore, data from The Cancer Genome Atlas revealed that CDKN2B‐AS1 expression levels were elevated in HCC tissues compared to normal tissues and were correlated with advanced T stages, high histological grades and poor prognoses. Our findings suggest that CDKN2B‐AS1 levels and its polymorphic variants at rs564398 and rs1537373 may influence the clinicopathological development and progression of HCC in a Taiwanese population.
Publisher
John Wiley & Sons, Inc,John Wiley and Sons Inc
Subject
/ Alcohol
/ Biobanks
/ Cancer
/ Carcinoma, Hepatocellular - genetics
/ Carcinoma, Hepatocellular - pathology
/ clinicopathologic progression
/ cyclin‐dependent kinase inhibitor 2B antisense RNA 1
/ Female
/ Females
/ Gender
/ Gene Expression Regulation, Neoplastic
/ Genes
/ Genetic Predisposition to Disease
/ Genotype
/ Humans
/ Kinases
/ Male
/ Males
/ Original
/ Polymorphism, Single Nucleotide - genetics
/ RNA
/ RNA, Long Noncoding - genetics
/ Single-nucleotide polymorphism
/ Smoking
/ Software
We currently cannot retrieve any items related to this title. Kindly check back at a later time.